Johns Hopkins University

A Johns Hopkins University study will track 10,000 medical marijuana patients for a year to analyze cannabis therapy's effectiveness and impact, while collecting data on dosage, methods, product composition, drug interactions and treatment details. As part of a larger Cannabis and Health...

Johns Hopkins University’s new congressional briefings series chapter, “What’s next for psychedelics,” covered a wide range of topics including clinical research specificities, therapists' training, policy hurdles, potential economic impact and necessary safeguards. The...

Israeli psychedelics biotech Clearmind Medicine (NASDAQ: CMND) has inked a research agreement with Johns Hopkins University School of Medicine (JHU) to conduct the first-in-human Phase I/IIa clinical trial on its proprietary MEAI-based compound CMND-100 for the potential treatment of Alcohol Use...

Renowned economist Steve Hanke warns of an imminent recession, indicating that stocks are overpriced and expected to return less than bonds. What Happened: Hanke, a professor of applied economics at Johns Hopkins University, anticipates a recession in the first half of 2024. He...

Colorado and Leiden-based biotech company Mydecine Innovations Group (OTC: MYCOF) has shared its financial results and business highlights for the period ended December 31, 2022. In ciphers: Total assets of $4.6 (CA$6.2) million as of Dec. 2022, of which cash constituted $8,216; compared to $3.8...

Steve Hanke, the professor of Applied Economics at Johns Hopkins University, reportedly said with the U.S. money supply contracting at an unprecedented rate, a recession will be right around the corner. What Happened: "The money supply changes eventually get transmitted first with a lag of about...

Steve Hanke, a professor of Applied Economics at Johns Hopkins University, has criticized the Federal Reserve’s monetary policy and President Joe Biden’s administration for a sharp drop in deal activity last year. Hanke cited a Bloomberg article from...

Steve Hanke, Professor of Applied Economics at Johns Hopkins University, has reiterated his skepticism about the impact of Western sanctions on the oil market stating that it would be the customers who would bear the brunt of these actions. What Happened: Citing a Wall Street Journal report that...

A new study analyzed the prevalence of cannabis vaping, cases of e-cigarette or vaping product-use-associated lung injury (EVALI), and marijuana laws in 13 states. Researchers used data from the 2019 Behavioral Risk Factor Surveillance System (BRFSS) and the Centers for Disease Control and...

Biotech company Mydecine Innovations Group (OTC: MYCOF) received FDA approval for their novel proprietary MYCO-001. This is the first clearance of the company’s drug product.  Mydecine focuses on developing first and second-generation novel therapeutics for the treatment of...

Psilocybin received yet another confirmation of its beneficial effects in the treatment of major depressive disorder, this time, in the long term. A new Johns Hopkins review study found that the positive effects of just two sessions of psilocybin-assisted psychotherapy can last for over one year in...

Cannabis is becoming universally known as a mood enhancer and anxiety-reducing substance.  However, the plant notoriously lacks clinical research to inform its safe and correct use in specific psychiatric disorders like anxiety and depression. A new study published last month is shedding light...

Michigan Senators Jeff Irwin (D-Ann Arbor) and Adam Hollier (D-Detroit) co-sponsored and introduced legislation last week that would decriminalize the use of psilocybin and mescaline and allow the possession, cultivation and delivery of these two types of psychedelics. In an...

On Wednesday, PharmaDrug Inc. (CSE: PHRX) (OTCPINK: LMLLF), a company researching DMT and other psychedelics for medical purposes, announced a new clinical trial agreement with Johns Hopkins University, one of the leading research institutions in the space. The research will encompass a clinical...

Mydecine Innovations Group (NEO: MYCO) (OTCPINK: MYCOF) has signed a five-year research agreement with Johns Hopkins University (JHU) School of Medicine, to study the application of psychedelics molecules and therapies in smoking cessation. The research will be led by Dr. Matthew W. Johnson,...